Monday, February 18, 2019
GCR Live Pharmaceuticals, Thursday, 28 February 2019, 2112 Pennsylvania Avenue, Washington, DC
Thursday, 28 February 2019, 2112 Pennsylvania Avenue, NW Washington, DC 20037
GCR is delighted to host the inaugural GCR Live Pharmaceuticals event on Thursday, 28 February 2019, chaired by J. Mark Gidley, of White & Case and Christine Siegwarth Meyer, of NERA Economic Consulting. The conference is designed to create a forum for antitrust professionals in the pharmaceuticals sector to come together and hear from the leading names in the space. It promises to be an insightful conference for lawyers specialising in both defendant and plaintiff work, in-house practitioners, consultants, industry professionals and service providers. Topics for discussion include pricing cases and what they mean for the future of pharma; and the costs and pitfalls of innovation in the industry. The conference is expected to bring in audience members from across the US and internationally, allowing delegates to connect with and learn from like-minded individuals.
E-mail Tel: +44 20 3780 4183
Chairs
White & Case, Washington, DC
J. Mark Gidley chairs the White & Case Global Antitrust/Competition practice, which is the only such practice to have been named Competition Group of the Year for seven years by Law360. His practice focuses on mergers and acquisitions, cartel cases, class actions, and pharmaceutical antitrust cases, with an emphasis on trying antitrust cases.
NERA Economic Consulting, New York
Featured as one of Global Competition Review's "Women in Antitrust," Dr. Christine Meyer is considered one of the foremost testifying economists in the areas of complex commercial litigation involving intellectual property, antitrust claims, and commercial damages. In the area of intellectual property, Dr. Meyer has analyzed damages and provided expert testimony concerning issues arising from patent, trademark, and copyright infringement, the misappropriation of trade secrets, and breaches of contract. She has considerable expertise in analyzing lost profits, reasonable royalties, price erosion, commercial success, and irreparable harm.
Keynote Speaker
Paul Csiszár
Director, Directorate General for Competition of the European Commission, Brussels
After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the Bar in 1986 in California he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Central Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as Director of "Basic Industries, Manufacturing and Agriculture" at the Directorate General for Competition of the European Commission.
Speakers
Cleary Gottlieb Steen & Hamilton, Washington, DC
Kathleen Bradish’s practice focuses on antitrust matters, including mergers, litigation, and government investigations. Kathleen originally joined Cleary Gottlieb Steen & Hamilton in 2005 and became counsel in 2014. In 2015, she joined the U.S. Department of Justice.
Most recently, she was Assistant Chief of the DOJ Antitrust Division’s International Section. In that capacity, she served as deputy chief handling the Antitrust Division’s international relations. She was responsible for presenting the enforcement views in international settings and within U.S. agencies. Between 2015 and 2018, she was International Counsel in the DOJ’s Antitrust Division and led the Justice Department’s relationship with Canadian, Australian, and New Zealand antitrust authorities and worked extensively on matters involving China. She also worked on the revision of DOJ-FTC International Enforcement and Cooperation Guidelines.
Kathleen returned to Cleary Gottlieb Steen & Hamilton as a counsel in 2018.
Dechert, Washington, DC
Mike Cowie has handled strategic projects for some of the world’s largest and most successful companies. His advice builds upon insights gained while directing investigations for the government.
Mr. Cowie served in the Federal Trade Commission’s Bureau of Competition as Assistant Director, where he managed a 25-attorney team responsible for antitrust merger investigations. Mr. Cowie earlier served as the FTC’s Senior Litigation Counsel responsible for leading the Commission’s antitrust litigation. The FTC awarded Mr. Cowie several honors, including the FTC’s Meritorious Service and Superior Service awards, and selected him to represent the FTC in its Merger Investigation Best Practices Initiative. Mr. Cowie has been called upon to testify on antitrust matters before the U.S. Congress and in statehouse and has received honors or recognition from the Financial Times, Global Competition Review, Chambers, and The Deal.
Deputy Chief Trial Counsel, Federal Trade Commission, Virginia
Thomas Dillickrath
Deputy Chief Trial Counsel, Federal Trade Commission, Virginia
Global Antitrust Counsel, Intel, Santa Clara
David Emanuelson
Global Antitrust Counsel, Intel, Santa Clara
David Emanuelson is the Global Antitrust Counsel at Intel Corporation. In this role, he advises on a broad range of antitrust areas including M&A, litigation, and compliance, focusing on Intel’s Data Center Group. Prior to working at Intel, David was the lead Americas antitrust counsel for Novartis Corporation for approximately four years and spent over a decade in private practice in Washington D.C.
Professor of Economics, University of East Anglia, Norwich
Kai-Uwe Kühn
Professor of Economics, University of East Anglia, Norwich
Reed Smith, Washington, DC
Ed co-leads our Antitrust & Competition Team in the Global Regulatory Enforcement Group, and has over three decades of experience defending clients in antitrust class actions and other antitrust and commercial litigation, and in criminal and civil antitrust investigations (both federal and state). He is recognized for his aggressive and successful pursuit of clients’ interests in litigation and investigations, and for his advocacy skills both in and out of the courtroom, including through trial. He also regularly represents clients in civil and criminal investigations by the DOJ Antirust Division, the FTC and states attorneys general.
Wilson Sonsini Goodrich & Rosati, Washington, DC
Seth Silber is a partner in the firm's Washington, D.C., office, where he focuses on advising clients in the pharmaceutical and healthcare markets, including issues concerning pharmaceutical patent settlements, mergers and acquisitions, and anticompetitive conduct. He regularly represents clients before both the Federal Trade Commission and U.S. Department of Justice.
Seth joined Wilson Sonsini Goodrich & Rosati in September 2006 after serving for six years at the Federal Trade Commission (FTC). During his tenure at the FTC, Seth obtained unique experience and insights into the commission's antitrust activities and enforcement practices, having served at all levels of the commission.
NERA Economic Consulting, Washington, DC
Dr. Chris Stomberg is an economic expert with expertise in health care and life sciences, who brings a quantitative and rigorous approach to his work. He has served as expert witness in several matters, and has led numerous litigation and consulting engagements. Chris Stomberg has focused on a range of issues affecting these industries.
Programme
8.45: Welcome coffee and registration
9.15: Chairs’ opening remarks
J. Mark Gidley, White & Case, Washington, DC
Christine Siegwarth Meyer, NERA Economic Consulting, New York
9.30: Keynote address
Paul Csiszár, Director, Directorate General for Competition of the European Commission, Brussels
10.15: Pricing cases: what do they mean for the future of pharma?
The scrutiny of pricing in the pharmaceuticals sector has, if anything, become fiercer in 2018. How has this enforcement by the agencies and court decisions from private litigation affected the industry and its business practices?
Questions the panel are expected to discuss include:
- What is the effect of industry consolidation on drug pricing?
- How are the agencies evaluating the effect of mergers on short-term and longer-term pricing?
- How has alleged collusion in the generic drugs market affected pricing, and how will those cases affect future enforcement?
- How effective are “pay-for-delay” settlements in today’s industry?
Moderator:
Seth Silber, Wilson Sonsini Goodrich & Rosati, Washington, DC
Panellists:
Thomas Dillickrath, Deputy Chief Trial Counsel, Federal Trade Commission, Virginia
Edward Schwartz, Reed Smith, Washington, DC
Chris Stomberg, NERA Economic Consulting, Washington, DC
11.30: Coffee break and welcome from Ken Reinker, Cleary Gottlieb Steen & Hamilton
12.00: Innovation: a double-edged sword?
Innovation is commonly accepted as beneficial for consumers and the market, but pharmaceutical companies have also been accused of using innovation and patents as an anti-competitive sword against potential competitors. How can companies understand what is ‘good’ and ‘bad’ innovation?
Questions the panel are expected to discuss include:
- Is the pharmaceutical industry in need of more regulation - or less?
- Is product hopping to extend patent life a clever tactic, or deleterious for the market?
- How are method of use patents seen by authorities and courts?
- What has been and will be the impact of alleged sham patent litigation?
- How should innovation be considered in merger review in the pharma sector?
Moderator:
Kathleen Bradish, Cleary Gottlieb Steen & Hamilton, Washington, DC
Panellists:
Mike Cowie, Dechert, Washington, DC
David Emmanuelson, Global Antitrust Counsel, Intel, California
J. Mark Gidley, White & Case, Washington, DC
Kai Uwe-Kuhn, Professor of Economics, University of East Anglia, Norwich
13.15: Chairs’ closing remarks
J. Mark Gidley, White & Case, Washington, DC
Christine Siegwarth Meyer, NERA Economic Consulting, New York
13.30: Networking lunch
https://lawprofessors.typepad.com/antitrustprof_blog/2019/02/gcr-live-pharmaceuticals-thursday-28-february-2019-2112-pennsylvania-avenue-washington-dc.html
